TY - JOUR
T1 - The WHO essential medicines list AWaRe book
T2 - from a list to a quality improvement system
AU - Sharland, Michael
AU - Zanichelli, Veronica
AU - Ombajo, Loice Achieng
AU - Bazira, Joel
AU - Cappello, Bernadette
AU - Chitatanga, Ronald
AU - Chuki, Pem
AU - Gandra, Sumanth
AU - Getahun, Haileyesus
AU - Harbarth, Stephan
AU - Loeb, Mark
AU - Mendelson, Marc
AU - Moja, Lorenzo
AU - Pulcini, Celine
AU - Sati, Hatim
AU - Tacconelli, Evelina
AU - Zeng, Mei
AU - Huttner, Benedikt
N1 - Funding Information:
MS reports grants from (1) the ADILA project (Antimicrobial Resistance, Prescribing, and Consumption Data to Inform Country Antibiotic Guidance and Local Action). Funder: Wellcome Trust (ADILA, Project number 222051/Z/20/Z) , Grant Holder St Georges, April 2022 to October 2025; (2) Impact of oral step down to amoxicillin or co-amoxiclav and the duration of antibiotic therapy on effectiveness, safety and selection of antibiotic resistance in severe childhood community-acquired pneumonia ( CAP ): a randomized controlled trial (PediCAP). Funder: EDCTP (Project, grant number RIA2017MC-2023) , Grant Holder: PENTA, April 2014 to March 2024; (3) NeoAMR Global Neonatal Sepsis Observational Study (NeoOBS): A prospective cohort study of sepsis in hospitalized neonates. Funder: DNDi (CHABU CHABUNeoOBs Neoobs1) , Grant Holder: GARDP, September 2017 to August 2024, (€1,826,618 total) – Chief Investigator (5%); and (4) Efficacy, safety and impact on AMR of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia ( CAP ): a randomised trial (CAP- IT ). Funder: NIHR- HTA (CAP-IT project number 13/88/11) , January 2017 to March 2020. MS also reports roles as (1) Chair (2011–2019) of the DH Expert Advisory Body Antimicrobial Prescribing, Resistance and Healthcare-associated Infection (APRHAI) and (2) Chair of the EML Antibiotic Working Group (2019–present). ML reports consulting fees from Sunovion , Paladin Labs, and the International Centre for Professional Development in Health and Medicine. MZ reports a role as Chair of the Paediatric Subgroup of the Chinese Society of Infectious Diseases. The other authors declare that they have no conflicts of interest. The AWaRe Book was funded by the Fleming Fund, the government of Germany, and GARD-P.
Funding Information:
MS reports grants from (1) the ADILA project (Antimicrobial Resistance, Prescribing, and Consumption Data to Inform Country Antibiotic Guidance and Local Action). Funder: Wellcome Trust (ADILA, Project number 222051/Z/20/Z), Grant Holder St Georges, April 2022 to October 2025; (2) Impact of oral step down to amoxicillin or co-amoxiclav and the duration of antibiotic therapy on effectiveness, safety and selection of antibiotic resistance in severe childhood community-acquired pneumonia (CAP): a randomized controlled trial (PediCAP). Funder: EDCTP (Project, grant number RIA2017MC-2023), Grant Holder: PENTA, April 2014 to March 2024; (3) NeoAMR Global Neonatal Sepsis Observational Study (NeoOBS): A prospective cohort study of sepsis in hospitalized neonates. Funder: DNDi (CHABU CHABUNeoOBs Neoobs1), Grant Holder: GARDP, September 2017 to August 2024, (€1,826,618 total) – Chief Investigator (5%); and (4) Efficacy, safety and impact on AMR of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised trial (CAP-IT). Funder: NIHR-HTA (CAP-IT project number 13/88/11), January 2017 to March 2020. MS also reports roles as (1) Chair (2011–2019) of the DH Expert Advisory Body Antimicrobial Prescribing, Resistance and Healthcare-associated Infection (APRHAI) and (2) Chair of the EML Antibiotic Working Group (2019–present). ML reports consulting fees from Sunovion, Paladin Labs, and the International Centre for Professional Development in Health and Medicine. MZ reports a role as Chair of the Paediatric Subgroup of the Chinese Society of Infectious Diseases. The other authors declare that they have no conflicts of interest. The AWaRe Book was funded by the Fleming Fund, the government of Germany, and GARD-P.
Publisher Copyright:
© 2022 European Society of Clinical Microbiology and Infectious Diseases
PY - 2022/12
Y1 - 2022/12
N2 - Antibiotics are often prescribed inappropriately, either when they are not necessary or with an unnecessarily broad spectrum of activity. AWaRe (AccessWatchReserve) is a system developed by WHO to classify antibiotics based on their spectrum of activity and potential for favouring the development of antibiotic resistance (Access: narrow spectrum/low potential for resistance; Watch: broader spectrum/higher potential for resistance; Reserve: last resort antibiotics to use very selectively). The WHO target is that by 2023, at least 60% of prescribed antibiotics globally should be from the Access category. The WHO AWaRe Book aims to improve empiric antibiotic prescribing by providing simple guidance for common infections based on the principles of AWaRe in alignment with the Model Lists of Essential Medicines for adults and children.
AB - Antibiotics are often prescribed inappropriately, either when they are not necessary or with an unnecessarily broad spectrum of activity. AWaRe (AccessWatchReserve) is a system developed by WHO to classify antibiotics based on their spectrum of activity and potential for favouring the development of antibiotic resistance (Access: narrow spectrum/low potential for resistance; Watch: broader spectrum/higher potential for resistance; Reserve: last resort antibiotics to use very selectively). The WHO target is that by 2023, at least 60% of prescribed antibiotics globally should be from the Access category. The WHO AWaRe Book aims to improve empiric antibiotic prescribing by providing simple guidance for common infections based on the principles of AWaRe in alignment with the Model Lists of Essential Medicines for adults and children.
KW - Antibiotic use
KW - Guidance
KW - Health policy
KW - Infectious disease
KW - Public health
UR - http://www.scopus.com/inward/record.url?scp=85139314122&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2022.08.009
DO - 10.1016/j.cmi.2022.08.009
M3 - Comment/debate
C2 - 36007869
AN - SCOPUS:85139314122
SN - 1198-743X
VL - 28
SP - 1533
EP - 1535
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 12
ER -